Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Completed Phase 2Phase 3 Interventional

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04899518
View directory record Official record
Conditions
Dry Eye
Interventions
ALY688 Ophthalmic Solution
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 10:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ocular Surface Dry Eye Microbiome

NCT02306668
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

NCT01129856
View directory record Official record
Conditions
Dry Eye
Interventions
Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The THINK Study Incidence of Neurotrophic Keratopathy)

NCT06482164
View directory record Official record
Conditions
Dry Eye
Interventions
Dry Eye Disease
Diagnostic Test
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Recruiting No phase listed Observational

Long-term Effects of Acoltremon vs. Control in Dry Eye Disease

NCT07659626
View directory record Official record
Conditions
Dry Eye
Interventions
Acoltremon 0.003%, Refresh classic preservative free
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease

NCT00848198
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
TearLab Corporation
Industry
Eligibility
18 Years to 79 Years
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Not applicable Interventional

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

NCT02100787
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TheraTears lubricating drops
Other
Lead sponsor
Jenkins Eye Care
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

NCT05031806
View directory record Official record
Conditions
Dry Eye Disease
Interventions
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnostic Evaluation of the Tear Film

NCT00761917
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Tear Film Analyzer
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
8
States / cities
Fayetteville, Arkansas • Morrow, Georgia • Oak Lawn, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 20, 2026, 10:33 AM EDT
Not listed Phase 4 Interventional

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

NCT04863742
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 20, 2026, 10:33 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

NCT05136924
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
Drug · Other
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Staining in a Healthy, Non-Dry Eye Population

NCT00643942
View directory record Official record
Conditions
Normal Healthy Eyes
Interventions
No intervention required
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Corneal Epithelial Thickness Mapping

NCT01712022
View directory record Official record
Conditions
Dry Eye and Contact Lens Wear
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • Latham, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 20, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

NCT01313351
View directory record Official record
Conditions
Dry Eye
Interventions
RPS InflammaDry Detector™
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
8
States / cities
Bradenton, Florida • Miami, Florida • Springfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 3 Interventional

Study of Rebamipide Eye Drops to Treat Dry Eye

NCT00201955
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Rebamipide 1%, Rebamipide 2%, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Placebo
Drug
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2010 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

NCT01057147
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 20, 2026, 10:33 AM EDT
Active, not recruiting No phase listed Observational

Study for Remote Investigation of Evaporative Dry Eye Disease

NCT06976515
View directory record Official record
Conditions
Evaporative Loss Dry Eye Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

NCT01319773
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety Safety of Nutritears® in Adults With Dry Eye Syndrome

NCT05481450
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Blink NutriTears, Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Lutz, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®

NCT07722624
View directory record Official record
Conditions
Dry Eye
Interventions
Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo®
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 10:33 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Anti-Glaucoma Medications on the Ocular Surface

NCT01315574
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 20, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Oct 20, 2026, 10:33 AM EDT